Franny Jongbloed

55 3 PROTECTION OF FASTING ON IRINOTECAN TOXICITY ALT AL vehicle F vehicle AL irinotecan F irinotecan 0 50 100 150 200 ** * ** U/l AST AL vehicle F vehicle AL irinotecan F irinotecan 0 200 400 600 800 1000 ** U/l LDH AL vehicle F vehicle AL irinotecan F irinotecan 0 1000 2000 3000 4000 * * * mmol/l Urea AL vehicle F vehicle AL irinotecan F irinotecan 0 5 10 15 20 ** * * mmol/l Creatinine AL vehicle F vehicle AL irinotecan F irinotecan 0 5 10 15 20 25 mmol/l Leukocytes AL vehicle F vehicle AL irinotecan F irinotecan 0 5 10 15 ** * Leukocytes*10^6/mL (A) (B) (C) Figure 1. (A) Liver function of the different experimental groups, measured via serum AST, ALT and LDH levels. (B) Measurement of kidney function of the experimental groups via serum urea and creatinine levels. (C) Leukocyte numbers of all the experimental groups. All values correspond to time point 12 hours after administration of either vehicle or irinotecan. AST = aspartate transaminase, ALT = alanine transaminase, LDH = lactate dehydrogenase. *= P< 0.05, **= P <0.01. Expression profiles To compare expression profiles between the different experimental groups, the numbers of differentially expressed probe sets (DEPS) were calculated. In the liver, 2,667 DEPS were found between the AL vehicle and AL irinotecan group, with 1,144 DEPS downregulated and 1,523 upregulated (Figure 2B). The number of DEPS between fasting vehicle and fasting irinotecan was 754, a 3.5-fold lower number than found in the AL vehicle and AL